Aclaris Therapeutics (ACRS): Multiple Catalysts Could Make 2H 2026 A Defining Period

Aclaris Therapeutics Inc. (ACRS) enters the second half of 2026 with strong momentum, backed by solid first-half execution and several key catalysts ahead. This clinical-stage biopharmaceutical company is focused on developing novel product candidates for immuno-inflammatory diseases.